By expenditures
| Name | Title | Type |
|---|---|---|
| Michael Pierce | Audit Partner | Auditee |
| Stephanie Smith | Chief Operating Officer | Auditee |
| Randy Milligan | Audit Partner | Auditee |
| No contacts on file | ||
| ID | Year | Date Accepted | Auditor | Spend |
|---|---|---|---|---|
| 382387 | 2025 | 2026-01-16 | LANDMARK PLC | $7.39M |
| 332309 | 2024 | 2024-12-12 | Landmark Plc | $7.83M |
| 298829 | 2023 | 2024-03-27 | Landmark Plc | $8.68M |
| 48059 | 2022 | 2023-03-30 | Landmark Plc | $8.12M |
| Audit | Year | Accepted | Finding | Ref | Severity | Repeat | Requirement |
|---|---|---|---|---|---|---|---|
| 382387 | 2025 | 2026-01-16 | 1169459 | 2025-002 | Material Weakness | Yes | E |
| 382387 | 2025 | 2026-01-16 | 1169458 | 2025-002 | Material Weakness | Yes | E |
| 382387 | 2025 | 2026-01-16 | 1169457 | 2025-002 | Material Weakness | Yes | E |
| 382387 | 2025 | 2026-01-16 | 1169456 | 2025-002 | Material Weakness | Yes | E |
| 382387 | 2025 | 2026-01-16 | 1169455 | 2025-002 | Material Weakness | Yes | E |
| 382387 | 2025 | 2026-01-16 | 1169454 | 2025-002 | Material Weakness | Yes | E |
| 382387 | 2025 | 2026-01-16 | 1169453 | 2025-002 | Material Weakness | Yes | E |
| 382387 | 2025 | 2026-01-16 | 1169452 | 2025-002 | Material Weakness | Yes | E |
| 382387 | 2025 | 2026-01-16 | 1169451 | 2025-001 | Material Weakness | Yes | N |
| 382387 | 2025 | 2026-01-16 | 1169450 | 2025-001 | Material Weakness | Yes | N |
| 382387 | 2025 | 2026-01-16 | 1169449 | 2025-001 | Material Weakness | Yes | N |
| 382387 | 2025 | 2026-01-16 | 1169448 | 2025-001 | Material Weakness | Yes | N |
| 382387 | 2025 | 2026-01-16 | 1169447 | 2025-001 | Material Weakness | Yes | N |
| 382387 | 2025 | 2026-01-16 | 1169446 | 2025-001 | Material Weakness | Yes | N |
| 382387 | 2025 | 2026-01-16 | 1169445 | 2025-001 | Material Weakness | Yes | N |
| 382387 | 2025 | 2026-01-16 | 1169444 | 2025-001 | Material Weakness | Yes | N |
| 48059 | 2022 | 2023-03-30 | 627481 | 2022-001 | Significant Deficiency | - | ABFGH |
| 48059 | 2022 | 2023-03-30 | 51039 | 2022-001 | Significant Deficiency | - | ABFGH |